Hormone therapy and fatal breast cancer

Pharmacoepidemiology and Drug Safety

Volumn 19, Issue 5, 2010, Pages 440-447

  Norman, Sandra A ^a   Weber, Anita L ^a   Localio, A Russell ^a   Marchbanks, Polly A ^b   Ursin, Giske ^c,d   Strom, Brian L ^a   Weiss, Linda K ^e   Burkman, Ronald T ^f   Bernstein, Leslie ^c,g   Deapen, Dennis M ^c   Folger, Suzanne G ^b   Simon, Michael S ^h   Nadel, Marion R ⁱ  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b NATIONAL CENTER FOR CHRONIC DISEASE PREVENTION AND HEALTH PROMOTION   (United States)

^c UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^d UNIVERSITY OF OSLO   (Norway)

^e NATIONAL CANCER INSTITUTE   (United States)

^f BAYSTATE MEDICAL CENTER   (United States)

^g CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^h WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

ⁱ CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

Breast neoplasms; Case control; Death; Estrogen progestin combination therapy; Estrogen replacement therapy; Hormone replacement therapy; Menopause

Indexed keywords

ESTROGEN; GESTAGEN;

ADULT; ARTICLE; BREAST CANCER; CANCER INCIDENCE; CANCER MORTALITY; CANCER RISK; CANCER SCREENING; CONTROLLED STUDY; ESTROGEN THERAPY; FATALITY; FEMALE; HORMONE SUBSTITUTION; HUMAN; MAJOR CLINICAL STUDY; MAMMOGRAPHY; POSTMENOPAUSE; PRIORITY JOURNAL; RISK ASSESSMENT; TREATMENT DURATION;

ADULT; BREAST NEOPLASMS; CASE-CONTROL STUDIES; ESTROGEN REPLACEMENT THERAPY; ESTROGENS; FEMALE; HUMANS; INCIDENCE; LOGISTIC MODELS; MENOPAUSE; MIDDLE AGED; PHARMACOEPIDEMIOLOGY; PROGESTERONE CONGENERS; RISK; SEER PROGRAM; UNITED STATES;

EID: 77952749726     PISSN: 10538569     EISSN: 10991557     Source Type: Journal    
DOI: 10.1002/pds.1941     Document Type: Article

References (33)

1. MacLennan AH, Broadbent JL, Lester S, Moore V. Oral oestrogen and combined oestrogen/progestogen therapy versus placebo for hot flushes. Cochrane Database Syst Rev, 2004. http://www.cochrane.org/reviews/en/ab002978.html (accessed 27 September 2007).
2. Barrett-Connor E, Grady D, Stefanick M. The rise and fall of menopausal hormone therapy. Annu Rev Public Health 2005; 26: 115-140.
3. Newton KM, Reed SD, LaCroix AZ, Grothaus LC, Ehrlich K, Guiltinan J. Treatment of vasomotor symptoms of menopause with black cohosh, multibotanicals, soy, hormone therapy, or placebo. Ann Intern Med 2006; 145: 869-879.
4. Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, Jackson RD, Beresford SA, Howard BV, Johnson KC, Kotchen JM, Ockene J. Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002; 288: 321-333.
5. Guay MP, Dragomir A, Pilon D, Moride Y, Perreault S. Changes in pattern of use, clinical characteristics and persistence rate of hormone replacement therapy among postmenopausal women after the WHI publication. Pharmacoepidemiol Drug Saf 2007; 16: 17-27.
6. Glass AG, Lacey JVJ, Carreon JD, Hoover RN. Breast cancer incidence, 1980-2006: combined roles of menopausal hormone therapy, screening mammography, and estrogen receptor status. J Natl Cancer Inst 2007; 99: 1152-1161.
7. Taylor AW, MacLennan AH, Avery JC. Postmenopausal hormone therapy: who now takes it and do they differ from non-users? Australian and New Zealand Journal of Obstetrics and Gynecology 2006; 46: 128-135.
8. Hersh AL, Stefanick ML, Stafford RS. National use of postmenopausal hormone therapy. Annual trends and response to recent evidence. JAMA 2004; 291: 47-53.
9. Kelly JP, Kaufman DW, Rosenberg L, Kelley K, Cooper SG, Mitchell AA. Use of postmenopausal hormone therapy since the Women's Health Initiative findings. Pharmacoepidemiol Drug Saf 2005; 14: 837-842.
10. Clarke CA, Glaser SL, Uratsu CS, Selby JV, Kushi LH, Herrinton L. Recent declines in hormone therapy utilization and breast cancer incidence: clinical and population-based evidence. J Clin Oncol 2006; 24: 49e-50e.
11. Buist DSM, Newton KM, Miglioretti DL, et al. Hormone therapy prescribing patterns in the United States. Obstet Gynecol 2004; 104: 1042-1050.
12. Newton KM, Buist DSM, Miglioretti DL, et al. The impact of comorbidities on hormone use after the 2002 release of the Women's Health Initiative. J Gen Intern Med 2005; 20: 350-356.
13. Helenius IM, Korenstein D, Halm EA. Changing use of hormone therapy among minority women since the Women's Health Initiative. Menopause 2007; 14: 216-222.
14. Grady D, Ettinger B, Tosteson ANA, Pressman A, Macer JL. Predictors of difficulty when discontinuing postmenopausal hormone therapy. Obstet Gynecol 2003; 102: 1233-1239.
15. Lawton B, Rose S, McLeod D, Dowell A. Changes in use of hormone replacement therapy after the report from the Women's Health Initiative: cross sectional survey of users. BMJ 2003; 327: 845-846.
16. Heitmann C, Greiser E, Doren M. The impact of the Women's Health Initiative Randomized Controlled Trial 2002 on perceived risk communication and use of postmenopausal hormone therapy in Germany. Menopause 2005; 12: 405-411.
17. Farquhar C, Marjoribanks J, Lethaby A, Lamberts Q, Suckling J. Cochrane HT Study Group. Long term hormone therapy for perimenopausal and postmenopausal women. Cochrane Database of Systematic Reviews 2005. http://www.cochrane.org/ reviews/en/ab004143.html (accessed 23 July 2007)
18. Vickers M, Meade T, Darbyshire J. WISDOM: history and early demise - was it inevitable? Climacteric 2002; 5: 317-325.
19. Vickers MR, MacLennan AH, Ford D, et al. Main morbidities recorded in the women's international study of long duration oestrogen after menopause (WISDOM): a randomised controlled trial of hormone replacement therapy in postmenopausal women. Br Med J 2007; 0: bmj.39266.425069.ADv 1.
20. Nanda K, Bastian L, Schulz K. Hormone replacement therapy and risk of death from breast cancer: a systematic review. Am J Obstet Gynecol 2002; 186: 325-334.
21. Beral V. Million Women Study Collaborators. Breast cancer and hormone replacement therapy in the Million Women Study. Lancet 2003; 362: 419-427.
22. Weiss LK, Burkman RT, Cushing-Haugen KL, et al. Hormone replacement therapy regimens and breast cancer risk. Obstet Gynecol 2002; 100: 1148-1158.
23. Daling JR, Malone KE, Doody DR, et al. Relation of regimens of combined hormone replacement therapy to lobular, ductal, and other histologic types of breast carcinoma. Cancer 2002; 95: 2455-2464.
24. Marchbanks PA, McDonald JA, Wilson HG, et al. The NICHD Women's Contraceptive and Reproductive Experiences Study: methods and operational results. Ann Epidemiol 2002; 12: 213-221.
25. Marchbanks PA, McDonald JA, Wilson HG, et al. Oral contraceptives and the risk of breast cancer. N Engl J Med 2002; 346: 2025-2032.
26. Weiss N, Lazovich D. Case-control studies of screening efficacy: the use of persons newly diagnosed with cancer who later sustain an unfavorable outcome. Am J Epidemiol 1996; 143: 319-322.
27. Ries L, Eisner M, Kosary C, et al. SEER Cancer Statistics Review, 1975-2001. National Cancer Institute: Bethesda, MD, 2004.
28. Wingo PA, Ory HW, Layde PM, et al. The evaluation of the data collection process for a multicenter, population-based case-control design. Am J Epidemiol 1988; 128: 206-217.
29. West SL, Strom BL, Poole C. Validity of pharmacoepidemiology drug and diagnosis data (p 661-705). In Pharmacoepidemiology, (3rd edn), Strom B (ed.). John Wiley: Sussex, 2000.
30. Colditz GA. Estrogen, estrogen plus progestin therapy, and risk of breast cancer. Clin Cancer Res 2005; 11: 909s-917s.
31. Norman SA, Localio AR,Weber AL, et al. Protection of mammography screening against death from breast cancer in women aged 40-64 years. Canc Causes Contr 2007; 18: 909-918.
32. Pentti K, Honkanen R, Tuppurainen MT, Sandini L, Kroger H, Saarikoski S. Hormone replacement therapy and mortality in 52- to 70-yearold women: the Kuopio Osteoporosis Risk Factor and Prevention Study. Eur J Endocrinol 2006; 154: 101-107.
33. Antoine C, Liebens F, Carly B, Pastijn A, Rozenberg S. Influence of HRT on prognostic factors for breast cancer: a systematic review after the Women's Health Initiative. Hum Reprod 2004; 19: 741-756.